The Quality Control of Micro- and Nanomedicines: Compliance with Regulatory Guidelines

Abstract

Carrier-based micro- and nanomedicines, such as microspheres, liposomes, and micelles, offer enhanced benefits over traditional medications, including improved bioavailability, targeted delivery, and reduced toxicity. Unlike conventional drugs, the particle size, shape, surface charge, and surface chemical properties of carrier-based micro/nanomedicines are key factors in determining their efficacy and toxicity. Even minor deviations in their preparation can significantly impact their in vivo performance. Therefore, the quality control of carrier-based micro/nanomedicines is more complicated than for conventional drugs. Regulatory authorities from the United States and China have established guidelines for their quality assessment. These guidelines categorize quality indicators into basic characteristics such as pH, viscosity, microbial limits, and nano-specific characteristics, including particle size, morphology, and stability. This review summarizes the significance and methodologies for evaluating these characteristics based on pharmacopeias and guidelines, emphasizing the distinct quality control requirements for different types of carrier-based micro- and nanomedicines.

Keywords

micromedicines - nanomedicines - quality control - guidelines - regulatory authorities

Publikationsverlauf

Eingereicht: 24. November 2024

Angenommen: 01. April 2025

Artikel online veröffentlicht:
21. Mai 2025

• References

• 1 Sainz V, Conniot J, Matos AI. et al. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun 2015; 468 (03) 504-510
• 2 Center for Drug Evaluation. National Medical Products Administration. Technical guidance for quality control study of nano drugs (interim) [in Chinese]. Accessed August 27, 2021 at: https://www.cde.org.cn/main/news/listpage/3cc45b396497b598341ce3af000490e5
• 3 Center for Drug Evaluation, National Medical Products Administration. Technical requirements for consistency evaluation of the quality and efficacy of generic chemical injections [in Chinese]. Accessed May 14, 2020 at: https://www.cde.org.cn/main/news/listpage/3cc45b396497b598341ce3af000490e5
• 4 Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. Pharmaceutics 2022; 14 (04) 883
• 5 Danhier F, Lecouturier N, Vroman B. et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 2009; 133 (01) 11-17
• 6 Nemutlu E, Eroğlu İ, Eroğlu H, Kır S. In vitro release test of nano-drug delivery systems based on analytical and technological perspectives. Curr Anal Chem 2019; 15: 373-409
• 7 Weng J, Tong HHY, Chow SF. In vitro release study of the polymeric drug nanoparticles: development and validation of a novel method. Pharmaceutics 2020; 12 (08) 732
• 8 Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M. Drug release study of the chitosan-based nanoparticles. Heliyon 2021; 8 (01) e08674
• 9 Markowicz-Piasecka M, Kubisiak M, Asendrych-Wicik K. et al. Long-acting injectable antipsychotics-a review on formulation and in vitro dissolution. Pharmaceutics 2023; 16 (01) 28
• 10 Wallace SJ, Li J, Nation RL, Boyd BJ. Drug release from nanomedicines: Selection of appropriate encapsulation and release methodology. Drug Deliv Transl Res 2012; 2 (04) 284-292
• 11 Gupta R, Chen Y, Xie H. In vitro dissolution considerations associated with nano drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021; 13 (06) e1732
• 12 Luo JY, Wu CM, Xu TW, Wu YH. Diffusion dialysis-concept, principle and applications. J Membr Sci 2011; 366: 1-16
• 13 Wang X, Anton H, Vandamme T, Anton N. Updated insight into the characterization of nano-emulsions. Expert Opin Drug Deliv 2023; 20 (01) 93-114
• 14 Gómez-Lázaro L, Martín-Sabroso C, Aparicio-Blanco J, Torres-Suárez AI. Assessment of in vitro release testing methods for colloidal drug carriers: the lack of standardized protocols. Pharmaceutics 2024; 16 (01) 103
• 15 Wolska E, Szymańska M. Comparison of the in vitro drug release methods for the selection of test conditions to characterize solid lipid microparticles. Pharmaceutics 2023; 15 (02) 511
• 16 Ghaferi M, Asadollahzadeh MJ, Akbarzadeh A, Ebrahimi Shahmabadi H, Alavi SE. Enhanced efficacy of pegylated liposomal cisplatin: in vitro and in vivo evaluation. Int J Mol Sci 2020; 21 (02) 559
• 17 Ma Y, Cai F, Li Y, Chen J, Han F, Lin W. A review of the application of nanoparticles in the diagnosis and treatment of chronic kidney disease. Bioact Mater 2020; 5 (03) 732-743
• 18 Falcao L, Gago LG, Astudillo D. et al. Influence of peritoneal residual volume on the results of the peritoneal equilibration test. Prospective study. Nefrologia (Engl Ed) 2023; 43 (02) 189-196
• 19 Gu Y, Wen H, Zhang Y. et al. Studies of anticancer activity in vivo and in vitro behaviors of liposomes encapsulated iridium(III) complex. Eur J Biochem 2021; 26 (01) 109-122
• 20 Davoodi P, Lee LY, Xu Q. et al. Drug delivery systems for programmed and on-demand release. Adv Drug Deliv Rev 2018; 132: 104-138
• 21 Zhang GH, Vadino WA, Yang TT, Cho WP, Chaudry IA. Evaluation of the flow-through cell dissolution apparatus: effects of flow rate, glass beads and tablet position on drug release from different type of tablets. Drug Dev Ind Pharm 1994; 20: 2063-2078
• 22 D'Souza S. A review of in vitro drug release test methods for nano-sized dosage forms. Adv Pharm 2014; 2014: 304757
• 23 Nothnagel L, Wacker MG. How to measure release from nanosized carriers?. Eur J Pharm Sci 2018; 120: 199-211
• 24 Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Front Chem 2018; 6: 360
• 25 Vaidya B, Nayak MK, Dash D, Agrawal GP, Vyas SP. Development and characterization of highly selective target-sensitive liposomes for the delivery of streptokinase: in vitro/in vivo studies. Drug Deliv 2016; 23 (03) 801-807
• 26 Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater 2013; 12 (11) 991-1003
• 27 Food and Drug Administration. Liposome drug products, chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability and labeling documentation. April 2018
• 28 Danaei M, Dehghankhold M, Ataei S. et al Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 2018; 10 (02) 57
• 29 Center for Drug Evaluation, National Medical Products Administration. National Medical Products Administration. Technical guidelines for research on paclitaxel (albumin-bound) generic drugs for injection [in Chinese]. Accessed January 8, 2020 at: https://www.cde.org.cn/main/news/listpage/3cc45b396497b598341ce3af000490e5
• 30 Food and Drug Administration. Office of Generic Drugs FY 2016 Regulatory Science Research Report. Nanotechnology: Physiochemical Characterization of Nano-Sized Drug Products. . Accessed January 8, 2025 at: https://www.fda.gov/industry/generic-drug-user-fee-amendments/office-generic-drugs-fy-2016-regulatory-science-research-report
• 31 Li J, Huo M, Wang J. et al. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 2012; 33 (07) 2310-2320
• 32 Chakraborty S, Panigrahi PK. Stability of nanofluid: a review. Appl Therm Eng 2020; 174: 115259-115275
• 33 Xu R. Light scattering: a review of particle characterization applications. Particuology 2015; 18: 11-21
• 34 Center for Drug Evaluation, National Medical Products Administration. Technical guidelines for liposomal drug quality control research [in Chinese]. Accessed October 19, 2023 at: https://www.cde.org.cn/main/news/listpage/3cc45b396497b598341ce3af000490e5
• 35 Lv Y, He H, Qi J. et al. Visual validation of the measurement of entrapment efficiency of drug nanocarriers. Int J Pharm 2018; 547 (1-2): 395-403
• 36 Ong SG, Ming LC, Lee KS, Yuen KH. Influence of the encapsulation efficiency and size of liposome on the oral bioavailability of griseofulvin-loaded liposomes. Pharmaceutics 2016; 8 (03) 25
• 37 Ran C, Chen D, Xu M, Du C, Li Q, Jiang Y. A study on characteristic of different sample pretreatment methods to evaluate the entrapment efficiency of liposomes. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1028: 56-62
• 38 Li X, Tang W, Jiang Y, Cheng L. Determination of content and entrapment efficiency of transferrin modified vincristine-tetrandrine liposomes [in Chinese]. China Pharmacy 2016; 22: 3034-3036
• 39 Owen SC, Chan DPY, Shoichet MS. Polymeric micelle stability. Nano Today 2012; 7: 53-65
• 40 Grit M, Crommelin DJ. Chemical stability of liposomes: implications for their physical stability. Chem Phys Lipids 1993; 64 (1–3): 3-18
• 41 Pajean M, Huc A, Herbage D. Stabilization of liposomes with collagen. Int J Pharm 1991; 77 (01) 31-40
• 42 Pietzyk B, Henschke K. Degradation of phosphatidylcholine in liposomes containing carboplatin in dependence on composition and storage conditions. Int J Pharm 2000; 196 (02) 215-218
• 43 Li W, Chen J, Zhao S. et al. High drug-loaded microspheres enabled by controlled in-droplet precipitation promote functional recovery after spinal cord injury. Nat Commun 2022; 13 (01) 1262-1289
• 44 Sánchez A, Tobío M, González L, Fabra A, Alonso MJ. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci 2003; 18 (3-4): 221-229
• 45 Shen J, Burgess DJ. Accelerated in-vitro release testing methods for extended-release parenteral dosage forms. J Pharm Pharmacol 2012; 64 (07) 986-996
• 46 Hickey T, Kreutzer D, Burgess DJ, Moussy F. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials 2002; 23 (07) 1649-1656
• 47 Le J, Zhang X, Lu WY. et al. Using double zero-order model to test the release of dexamethasone implants [in Chinese]. Yao Xue Xue Bao 2020; 55 (06) 1306-1311
• 48 Schutzman R, Shi NQ, Olsen KF. et al. Mechanistic evaluation of the initial burst release of leuprolide from spray-dried PLGA microspheres. J Control Release 2023; 361: 297-313
• 49 Mok ZH. The effect of particle size on drug bioavailability in various parts of the body. Pharmaceutical Science Advances 2024; 2: 100031
• 50 Maderuelo C, Zarzuelo A, Lanao JM. Critical factors in the release of drugs from sustained release hydrophilic matrices. J Control Release 2011; 154 (01) 2-19
• 51 Rawat A, Stippler E, Shah VP, Burgess DJ. Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal Consta. Int J Pharm 2011; 420 (02) 198-205
• 52 Rawat A, Bhardwaj U, Burgess DJ. Comparison of in vitro-in vivo release of Risperdal(®) Consta(®) microspheres. Int J Pharm 2012; 434 (1-2): 115-121
• 53 Rawat A, Burgess DJ. Effect of physical ageing on the performance of dexamethasone loaded PLGA microspheres. Int J Pharm 2011; 415 (1–2): 164-168
• 54 Sandri G, Bonferoni MC, Ferrari F, Rossi S, Caramella CM. The role of particle size in drug release and absorption. In: Merkus HG, Meesters GMH. eds. Particulate Products: Tailoring Properties for Optimal Performance. Cham: Springer International Publishing; 2014: 323-341
• 55 Geiser M. Update on macrophage clearance of inhaled micro- and nanoparticles. J Aerosol Med Pulm Drug Deliv 2010; 23 (04) 207-217
• 56 Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release 2001; 73 (2-3): 121-136
• 57 Werner ME, Cummings ND, Sethi M. et al. Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013; 86 (03) 463-468
• 58 Varela-Moreira A, van Leur H, Krijgsman D. et al. Utilizing in vitro drug release assays to predict in vivo drug retention in micelles. Int J Pharm 2022; 618: 121638
• 59 Kumar S, Allard JF, Morris D, Dory YL, Lepage M, Zhao Y. Near-infrared light sensitive polypeptide block copolymer micelles for drug delivery. J Mater Chem 2012; 22: 7252-7257
• 60 Gao X, Yu Z, Liu B, Yang J, Yang X, Yu Y. A smart drug delivery system responsive to pH/enzyme stimuli based on hydrophobic modified sodium alginate. Eur Polym J 2020; 133: 109779
• 61 Zheng X, Fang Z, Huang W. et al. Ionic co-aggregates (ICAs) based oral drug delivery: Solubilization and permeability improvement. Acta Pharm Sin B 2022; 12 (10) 3972-3985
• 62 Sheng Y, Zheng X, Li L, He H, Wu W, Lu Y. Ionic co-aggregates based intravenous drug delivery: Evaluation on kinetics and distribution of the drug payloads and nanocarriers. Int J Pharm 2024; 665: 124657
• 63 Cai Y, Ji X, Zhang Y. et al. Near-infrared fluorophores with absolute aggregation-caused quenching and negligible fluorescence re-illumination for in vivo bioimaging of nanocarriers. Aggregate (Hoboken) 2023; 4: e277-e289
• 64 Organization of the Ministry of Health. Labour and Welfare. Guideline for the Development of Liposome Drug Products. . Accessed May 8, 2025 at: https://www.nihs.go.jp/drug/section4/nanomedicine_e/160328_MHLW_liposome_guideline.pdf
• 65 Food and Drug Administration. FDA guidance for industry: Liposome drug products: chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation. Accessed May 8, 2025 at: https://www.fda.gov/media/70837/download
• 66 Center for Drug Evaluation, National Medical Products Administration. National medical products administration, technical guidelines for doxorubicin hydrochloride liposome injection generic drug research (trial) [in Chinese]. Accessed October 21, 2020 at: https://www.cde.org.cn/main/news/listpage/3cc45b396497b598341ce3af000490e5
• 67 Janas C, Mast MP, Kirsamer L. et al. The dispersion releaser technology is an effective method for testing drug release from nanosized drug carriers. Eur J Pharm Biopharm 2017; 115: 73-83
• 68 Jablonka L, Ashtikar M, Gao G. et al. Advanced in silico modeling explains pharmacokinetics and biodistribution of temoporfin nanocrystals in humans. J Control Release 2019; 308: 57-70
• 69 Jablonka L, Ashtikar M, Gao GF. et al. Predicting human pharmacokinetics of liposomal temoporfin using a hybrid in silico model. Eur J Pharm Biopharm 2020; 149: 121-134
• 70 Shabbits JA, Chiu GN, Mayer LD. Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J Control Release 2002; 84 (03) 161-170
• 71 Lu Y, Kim S, Park K. In vitro-in vivo correlation: perspectives on model development. Int J Pharm 2011; 418 (01) 142-148
• 72 Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol 2005; 391: 71-97
• 73 Barenholz Y. Doxil®–the first FDA-approved nano-drug: lessons learned. J Control Release 2012; 160 (02) 117-134
• 74 Lindner LH, Hossann M. Factors affecting drug release from liposomes. Curr Opin Drug Discov Devel 2010; 13 (01) 111-123